Novo Nordisk reports 2025 sales growth, cuts 2026 outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Novo Nordisk (NVO) Tops Q4 EPS by 10c; Lowers Outlook
February 3, 2026 12:05 PM ESTNovo Nordisk (NYSE: NVO) reported Q4 EPS of $1.02, $0.10 better than the analyst estimate of $0.92. Revenue for the quarter came in at $12.53 billion versus the consensus estimate of $11.99 billion.
GUIDANCE:
Adjusted sales growth for 2026, which excludes revenue from the reversal of 340B... More
